Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia

Rebekka Wegmann, Ximena Bonilla, Ruben Casanova, Stéphane Chevrier, Ricardo Coelho, Cinzia Esposito, Joanna Ficek-Pascual, Sandra Goetze, Gabriele Gut, Francis Jacob, Alice K. Jacobs, Jack Kuipers, Ulrike Lischetti, Julien Mena, Emanuela S. Milani, Michael Prummer, Jacobo Sarabia del Castillo, Franziska Singer, Sujana Sivapatham, Nora C. Toussaint, Olivér Vilinovszki, Mattheus H. E. Wildschut, Tharshika Thavayogarajah, Disha Malani, Ruedi Aebersold, Melike Ak, Faisal Alquaddoomi, Silvana I. Albert, Jonas Albinus, Ilaria Alborelli, Sonali Andani, Per-Olof Attinger, Marina Bacac, Daniel Baumhoer, Beatrice Beck‐Schimmer, Niko Beerenwinkel, Christian Beisel, Lara Bernasconi, Anne Bertolini, Bernd Bodenmiller, Lars Bosshard, Byron Calgua, Natalia Chicherova, Maya D’Costa, Esther Danenberg, Natalie R. Davidson, Monica-Andreea Drăgan, Reinhard Dummer, Stefanie Engler, Martin Erkens, Katja Eschbach, André Fedier, Pedro Ferreira, Anja Frei, Bruno S. Frey, Linda Grob, Detlef Günther, Pirmin Haeuptle, Viola Heinzelmann‐Schwarz, Sylvia Herter, René Holtackers, Tamara Huesser, Alexander Immer, Anja Irmisch, Tim M. Jaeger, Katharina Jahn, Alva Rani James, Philip Jermann, André Kahles, Abdullah Kahraman, Viktor H. Koelzer, Werner Kuebler, Christian P. Kunze, Christian Kurzeder, Kjong-Van Lehmann, Mitchell P. Levesque, Flavio C. Lombardo, Sebastian Lugert, Gerd Maass, Philipp Markolin, Martin Mehnert, Julian M. Metzler, Nicola Miglino, Holger Moch, Simone Muenst, Riccardo Murri, Charlotte K.y. Ng, Stefan Nicolet, Marta Nowak, Mónica Núñez López, Patrick G. A. Pedrioli, Lucas Pelkmans, Salvatore PiscuoglioNature Communications 2024 · DOI

Abstract

Deep single-cell multi-omic profiling offers a promising approach to understand and overcome drug resistance in relapsed or refractory (rr) acute myeloid leukemia (AML). Here, we combine single-cell ex vivo drug profiling (pharmacoscopy) with single-cell and bulk DNA, RNA, and protein analyses, alongside clinical data from 21 rrAML patients. Unsupervised data integration reveals reduced ex vivo response to the Bcl-2 inhibitor venetoclax (VEN) in patients treated with both a hypomethylating agent (HMA) and VEN, compared to those pre-exposed to chemotherapy or HMA alone. Integrative analysis identifies both known and unreported mechanisms of innate and treatment-related VEN resistance and suggests alternative treatments, like targeting increased proliferation with the PLK inhibitor volasertib. Additionally, high CD36 expression in VEN-resistant blasts associates with sensitivity to CD36-targeted antibody treatment ex vivo. This study demonstrates how single-cell multi-omic profiling can uncover drug resistance mechanisms and treatment vulnerabilities, providing a valuable resource for future AML research.

Introduction

Acute myeloid leukemia (AML) is a highly heterogeneous disease, making it exceptionally difficult to treat. While the Bcl-2 inhibitor Venetoclax has significantly improved patient outcomes, many individuals experience either innate resistance or eventual relapse. Traditional bulk molecular profiling—which analyzes a mixture of all cells in a sample—often misses the specific sub-clonal populations or cell states that drive this resistance. To address this, researchers have mapped the single-cell multi-omic landscape of drug resistance in relapsed or refractory (rr) AML, aiming to identify the molecular drivers of resistance and discover new therapeutic vulnerabilities.

Methods: The TuPro Pipeline

The study utilized a sophisticated pipeline called TuPro, designed to integrate multiple layers of biological information from patient samples. This platform combines functional drug testing with high-resolution molecular profiling:

  • Pharmacoscopy (PCY): An automated, image-based screening tool that tests the response of live patient cells to 79 different drugs ex vivo.
  • Single-cell Multi-omics: Simultaneous profiling of DNA (scDNA-seq), RNA (scRNA-seq), and proteins (CyTOF) to capture the state of individual leukemic cells.
  • Data Integration: By matching functional drug responses with molecular profiles, the researchers could pinpoint the exact characteristics of drug-resistant "blasts."
The TuPro pipeline integrates bulk and single-cell technologies to profile DNA, RNA, protein, and functional drug responses.

Characterizing the rrAML Cohort

The researchers analyzed 57 samples (blood and bone marrow) from 21 patients with rrAML. This cohort exhibited a diverse range of genetic alterations, including mutations in FLT3, DNMT3A, and RUNX1. A key finding from the integrated data was that patients previously treated with a combination of hypomethylating agents (HMA) and Venetoclax showed significantly reduced ex vivo responses to Venetoclax compared to those treated with chemotherapy or HMA alone.

Comprehensive overview of the rrAML cohort, including genetic alterations and technical validation across different single-cell platforms.

Key Insights into Venetoclax Resistance

The study revealed that Venetoclax resistance is not driven by a single mutation but rather by a shift in the cell's state toward a more "mature" myeloid phenotype.

  • CD36 as a Biomarker: High expression of CD36 (a fatty acid transporter) was identified as a hallmark of resistance. CD36 and the drug target BCL2 were found to be nearly mutually exclusive at the single-cell level.
  • Metabolic Rewiring: Resistant cells appear to "switch fuels," relying on oxidative phosphorylation (OXPHOS) and fatty acid uptake to survive when the BCL2 pathway is inhibited.

Identifying New Therapeutic Vulnerabilities

Importantly, the study identified "collateral sensitivities" in Venetoclax-resistant cells, offering potential "plan B" treatments:

  • PLK1 Inhibition: 75% of Venetoclax-resistant samples showed sensitivity to the PLK inhibitor volasertib.
  • CD36 Targeting: In samples with high CD36 expression, treatment with an anti-CD36 antibody successfully reduced the number of leukemic blasts ex vivo.
  • Clinical Feasibility: The researchers achieved a "vein-to-data" turnaround time of roughly two weeks, proving that deep multi-omic profiling is feasible within the timeframe required for clinical decision-making.

Conclusion and Future Directions

This research demonstrates that single-cell multi-omic profiling can uncover actionable drug resistance mechanisms and treatment vulnerabilities in AML. While the cohort size is relatively small, the findings regarding CD36 and PLK1 provide a strong foundation for future clinical trials. Future work will focus on validating these therapeutic strategies in larger cohorts and animal models to bring these personalized approaches to the clinic.

Summary updated

Abstract

Deep single-cell multi-omic profiling offers a promising approach to understand and overcome drug resistance in relapsed or refractory (rr) acute myeloid leukemia (AML). Here, we combine single-cell ex vivo drug profiling (pharmacoscopy) with single-cell and bulk DNA, RNA, and protein analyses, alongside clinical data from 21 rrAML patients. Unsupervised data integration reveals reduced ex vivo response to the Bcl-2 inhibitor venetoclax (VEN) in patients treated with both a hypomethylating agent (HMA) and VEN, compared to those pre-exposed to chemotherapy or HMA alone. Integrative analysis identifies both known and unreported mechanisms of innate and treatment-related VEN resistance and suggests alternative treatments, like targeting increased proliferation with the PLK inhibitor volasertib. Additionally, high CD36 expression in VEN-resistant blasts associates with sensitivity to CD36-targeted antibody treatment ex vivo. This study demonstrates how single-cell multi-omic profiling can uncover drug resistance mechanisms and treatment vulnerabilities, providing a valuable resource for future AML research.
BibTeX
@inproceedings{wegmann2024single,
  author = {Rebekka Wegmann and Ximena Bonilla and Ruben Casanova and Stéphane Chevrier and Ricardo Coelho and Cinzia Esposito and Joanna Ficek-Pascual and Sandra Goetze and Gabriele Gut and Francis Jacob and Alice K. Jacobs and Jack Kuipers and Ulrike Lischetti and Julien Mena and Emanuela S. Milani and Michael Prummer and Jacobo Sarabia del Castillo and Franziska Singer and Sujana Sivapatham and Nora C. Toussaint and Olivér Vilinovszki and Mattheus H. E. Wildschut and Tharshika Thavayogarajah and Disha Malani and Ruedi Aebersold and Melike Ak and Faisal Alquaddoomi and Silvana I. Albert and Jonas Albinus and Ilaria Alborelli and Sonali Andani and Per-Olof Attinger and Marina Bacac and Daniel Baumhoer and Beatrice Beck‐Schimmer and Niko Beerenwinkel and Christian Beisel and Lara Bernasconi and Anne Bertolini and Bernd Bodenmiller and Ximena Bonilla and Lars Bosshard and Byron Calgua and Natalia Chicherova and Maya D’Costa and Esther Danenberg and Natalie R. Davidson and Monica-Andreea Drăgan and Reinhard Dummer and Stefanie Engler and Martin Erkens and Katja Eschbach and Cinzia Esposito and André Fedier and Pedro Ferreira and Joanna Ficek-Pascual and Anja Frei and Bruno S. Frey and Sandra Goetze and Linda Grob and Gabriele Gut and Detlef Günther and Pirmin Haeuptle and Viola Heinzelmann‐Schwarz and Sylvia Herter and René Holtackers and Tamara Huesser and Alexander Immer and Anja Irmisch and Tim M. Jaeger and Katharina Jahn and Alva Rani James and Philip Jermann and André Kahles and Abdullah Kahraman and Viktor H. Koelzer and Werner Kuebler and Jack Kuipers and Christian P. Kunze and Christian Kurzeder and Kjong-Van Lehmann and Mitchell P. Levesque and Flavio C. Lombardo and Sebastian Lugert and Gerd Maass and Philipp Markolin and Martin Mehnert and Julien Mena and Julian M. Metzler and Nicola Miglino and Holger Moch and Simone Muenst and Riccardo Murri and Charlotte K.Y. Ng and Stefan Nicolet and Marta Nowak and Mónica Núñez López and Patrick G. A. Pedrioli and Lucas Pelkmans and Salvatore Piscuoglio},
  title = {{Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia}},
  booktitle = {Nature Communications},
  year = {2024},
  doi = {10.1038/s41467-024-53535-4},
}
Figure